D. Bahr

Performance of a shortened Scale for Assessment of Positive Symptoms for Parkinson's disease psychosis.

J. Cummings, B. Ravina, R. Mills, 2013, Parkinsonism & related disorders.

Improvement in wound healing, pain, and quality of life after 12 weeks of SNF472 treatment: a phase 2 open-label study of patients with calciphylaxis

A. Gold, P. Joubert, J. Perelló, 2019, Journal of Nephrology.

Pimavanserin, a Serotonin2A Receptor Inverse Agonist, for the Treatment of Parkinson's Disease Psychosis

J. Friedman, H. Meltzer, R. Mills, 2010, Neuropsychopharmacology.

Acute Cerebrovascular Disease in the Young: The Stroke in Young Fabry Patients Study

G. Deuschl, A. Metz, D. Krieger, 2013, Stroke.

2.277 OPTIMIZATION OF PHASE III STUDY DESIGN FOR PIMAVANSERIN IN THE TREATMENT OF PARKINSON'S DISEASE PSYCHOSIS (PDP)

R. Mills, H. Williams, D. Bahr, 2012 .

Improvement in wound healing, pain, and quality of life after 12 weeks of SNF472 treatment: a phase 2 open-label study of patients with calciphylaxis

A. Gold, P. Joubert, J. Perelló, 2019, Journal of Nephrology.